Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 112Leukemia, Lymphocytic, Chronic, B-Cell 111Leukemia 102Myelodysplastic Syndromes 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Lymphoma 77Lymphoma, Non-Hodgkin 73Multiple Myeloma 69Hodgkin Disease 67Lymphoma, Follicular 55Lymphoma, Mantle-Cell 52Leukemia, Myelogenous, Chronic, BCR-ABL Positive 51Myeloproliferative Disorders 50Congenital Abnormalities 47Lymphoma, Large B-Cell, Diffuse 46Lymphoma, B-Cell, Marginal Zone 45Leukemia, Myeloid, Accelerated Phase 43Leukemia, Myeloid, Chronic-Phase 42Burkitt Lymphoma 41Leukemia, Myelomonocytic, Chronic 40Blast Crisis 33Primary Myelofibrosis 32Lymphoma, Large-Cell, Immunoblastic 30Waldenstrom Macroglobulinemia 29Neoplasms, Plasma Cell 29Melanoma 29Anemia, Refractory, with Excess of Blasts 29Recurrence 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Myelodysplastic-Myeloproliferative Diseases 24

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × fludarabine phosphate × Clear all
NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
20 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡